HOUT-17. A PRELIMINARY DATA REPORT ON A PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA

Standard therapy for recurrent GBM is bevacizumab, a monoclonal VEGF inhibitor that targets tumor vasculature. The response to bevacizumab is transient and short-lived after which patients typically develop progressive physical and mental debilitation culminating in death. ERC1671 is an allogeneic/a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Bota, Daniela, Chung, Jinah, Carrillo, Jose, Kong, Xiao-Tang, Fu, Beverly, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil, Stathopoulos, Apostolos
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692303/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.448
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg